Ruvidar Demonstrates 7 Year Complete Response

A BCG-unresponsive bladder cancer patient achieved a 7-year complete response after one Ruvidar™ treatment activated by light. Theralase® plans regulatory submissions and expanded clinical trials in 2025–2026 for hard-to-treat cancers and infections.

Ruvidar Effective in the Treatment of Herpes

Ruvidar™ showed superior efficacy over Acyclovir and Abreva in treating HSV-1 in a mouse model. Theralase® plans topical formulation, toxicology, and Phase I/II trials pending funding in 2025.

Ruvidar™ Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it’s lead drug formulation, Ruvidar TM , has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 (“HSV-1“) than the currently approved standard of care drug, Acyclovir. Acyclovir is an antiviral drug used to slow the growth and spread of the HSV-1 virus in the body. Acyclovir will not cure herpes, but it can lessen the symptoms of the infection. It is used to treat infections caused by herpes viruses, such … Read More

Ruvidar Enhances Efficacy of Cancer Drug

June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.

Theralase® Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar™

Toronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated. Supported by current Good Manufacturing Practice (“cGMP”) analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM. Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, “Theralase®’s ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the … Read More

Theralase® 1Q2025 Financial Statements

Theralase® reported Q1 2025 results showing lower revenue and increased R&D expenses, ongoing Study II enrollment with promising bladder cancer interim data, continued HSV treatment development, and plans for Rutherrin® clinical trials starting early 2026 targeting multiple cancers.

Theralase® Provides Corporate Update

Theralase advances Ruvidar® trials for bladder and other cancers, targeting NDA submissions by 2026, launching multiple Phase I/II studies, seeking US listing, and pursuing international partnerships for commercialization and research collaboration.